Amgen price target raised to $275 from $256 at BofA
BofA raised the firm’s price target on Amgen (AMGN) to $275 from $256 and keeps an Underperform rating on the shares. Q4 results were slightly ...
BioPharma Dive23h
Amgen obesity drug on hold; Regeneron sets first dividend
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Accumulus Synergy Powers Industry’s First Digitally Generated Dossier to Nearly Two Dozen Countries Simultaneously
Leveraging the Accumulus platform, the digitally generated dossier created by Amgen using its proprietary AI and novel Structured Content and Data Management (SCDM) software is being reviewed by the ...